Diabetes & Metabolism Journal

Kyu Yong Cho (Cho KY)

2 Articles

Complications
Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease: Rimi Izumihara, Hiroshi Nomoto, Kenichi Kito, Yuki Yamauchi, Kazuno Omori, Yui Shibayama, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, So Nagai, Ichiro Sakuma, Akinobu Nakamura, Tatsuya Atsumi, on Behalf of the PARM-TD Study Group; Diabetes Metab J. 2024;48(3):473-481. Published online February 29, 2024; DOI: https://doi.org/10.4093/dmj.2023.0370

2,514 View
380 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Fibrates have renal toxicity limiting their use in subjects with chronic kidney disease (CKD). However, pemafibrate has fewer toxic effects on renal function. In the present analysis, we evaluated the effects of pemafibrate on the renal function of diabetic subjects with or without CKD in a real-world clinical setting.
Methods
We performed a sub-analysis of data collected during a multi-center, prospective, observational study of the effects of pemafibrate on lipid metabolism in subjects with type 2 diabetes mellitus complicated by hypertriglyceridemia (the PARM-T2D study). The participants were allocated to add pemafibrate to their existing regimen (ADD-ON), switch from their existing fibrate to pemafibrate (SWITCH), or continue conventional therapy (CTRL). The changes in estimated glomerular filtration rate (eGFR) over 52 weeks were compared among these groups as well as among subgroups created according to CKD status.
Results
Data for 520 participants (ADD-ON, n=166; SWITCH, n=96; CTRL, n=258) were analyzed. Of them, 56.7% had CKD. The eGFR increased only in the SWITCH group, and this trend was also present in the CKD subgroup (P<0.001). On the other hand, eGFR was not affected by switching in participants with severe renal dysfunction (G3b or G4) and/or macroalbuminuria. Multivariate analysis showed that being older and a switch from fenofibrate were associated with elevation in eGFR (both P<0.05).
Conclusion
A switch to pemafibrate may be associated with an elevation in eGFR, but to a lesser extent in patients with poor renal function.

Citations

Citations to this article as recorded by

Research hotspots and future trends in lipid metabolism in chronic kidney disease: a bibliometric and visualization analysis from 2004 to 2023
Ying Wang, Tongtong Liu, Weijing Liu, Hailing Zhao, Ping Li
Frontiers in Pharmacology.2024;[Epub] CrossRef
Impact of Conversion from Conventional Pemafibrate to Novel Pemafibrate XR on Hypertriglyceridemia: An Observational Retrospective Study
Yuki Hida, Teruhiko Imamura, Koichiro Kinugawa
Journal of Clinical Medicine.2024; 13(19): 5879. CrossRef

Drug/Regimen
Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial: Kyu Yong Cho, Akinobu Nakamura, Chiho Oba-Yamamoto, Kazuhisa Tsuchida, Shingo Yanagiya, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi; Diabetes Metab J. 2020;44(4):532-541. Published online November 22, 2019; DOI: https://doi.org/10.4093/dmj.2019.0093

6,800 View
177 Download
8 Web of Science
11 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

To explore the efficacy and safety of switching from once-daily basal insulin therapy to once-daily pre-meal injection insulin degludec/insulin aspart (IDegAsp) with respect to the glycemic control of participants with type 2 diabetes mellitus (T2DM).

Methods

In this multicenter, open-label, prospective, randomized, parallel-group comparison trial, participants on basal insulin therapy were switched to IDegAsp (IDegAsp group; n=30) or continued basal insulin (Basal group; n=29). The primary endpoint was the superiority of IDegAsp in causing changes in the daily blood glucose profile, especially post-prandial blood glucose concentration after 12 weeks.

Results

Blood glucose concentrations after dinner and before bedtime were lower in the IDegAsp group, and the improvement in blood glucose before bedtime was significantly greater in the IDegAsp group than in the Basal group at 12 weeks (−1.7±3.0 mmol/L vs. 0.3±2.1 mmol/L, P<0.05). Intriguingly, glycemic control after breakfast was not improved by IDegAsp injection before breakfast, in contrast to the favorable effect of injection before dinner on blood glucose after dinner. Glycosylated hemoglobin significantly decreased only in the IDegAsp group (58 to 55 mmol/mol, P<0.05). Changes in daily insulin dose, body mass, and recorded adverse effects, including hypoglycemia, were comparable between groups.

Conclusion

IDegAsp was more effective than basal insulin at reducing blood glucose after dinner and before bedtime, but did not increase the incidence of hypoglycemia. Switching from basal insulin to IDegAsp does not increase the burden on the patient and positively impacts glycemic control in patients with T2DM.

Citations

Citations to this article as recorded by

Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study
Na Yang, Lu Lv, Shu-Meng Han, Li-Yun He, Zi-Yi Li, Yu-Cheng Yang, Fan Ping, Ling-Ling Xu, Wei Li, Hua-Bing Zhang, Yu-Xiu Li
World Journal of Diabetes.2025;[Epub] CrossRef
Glycaemic outcomes in hospital with IDegAsp versus BIAsp30 premixed insulins
Joshua R. Walt, Julie Loughran, Spiros Fourlanos, Rahul D. Barmanray, Jasmine Zhu, Suresh Varadarajan, Mervyn Kyi
Internal Medicine Journal.2024; 54(8): 1329. CrossRef
The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
Ming Liu, Weijun Gu, Li Chen, Yanbing Li, Hongyu Kuang, Jianling Du, Agustina Alvarez, Felipe Lauand, Elisabeth Souhami, Jiewen Zhang, Weiya Xu, Qin Du, Yiming Mu
Diabetes, Obesity and Metabolism.2024; 26(9): 3791. CrossRef
Cutting-edge microneedle innovations: Transforming the landscape of cardiovascular and metabolic disease management
Xiaoning Zhang, Ming Li, Qiang Gao, Xiaoya Kang, Jingyao Sun, Yao Huang, Hong Xu, Jing Xu, Songren Shu, Jian Zhuang, Yuan Huang
iScience.2024; 27(9): 110615. CrossRef
Low fasting glucose‐to‐estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes
Han Na Jang, Ye Seul Yang, Tae Jung Oh, Bo Kyung Koo, Seong Ok Lee, Kyong Soo Park, Hak Chul Jang, Hye Seung Jung
Journal of Diabetes Investigation.2022; 13(1): 85. CrossRef
Comparing Time to Intensification between insulin Degludec/Insulin Aspart and Insulin Glargine
Rajiv Kovil
Journal of Diabetology.2022; 13(2): 171. CrossRef
Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns
Tevfik Demir, Serap Turan, Kursad Unluhizarci, Oya Topaloglu, Tufan Tukek, Dilek Gogas Yavuz
Frontiers in Endocrinology.2021;[Epub] CrossRef
Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
I. N. Dyakov, S. K. Zyryanov
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice.2021; 20(1): 4. CrossRef
Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
Shinje Moon, Hye-Soo Chung, Yoon-Jung Kim, Jae-Myung Yu, Woo-Ju Jeong, Jiwon Park, Chang-Myung Oh
Metabolites.2021; 11(9): 639. CrossRef
Insulin therapy in diabetic kidney disease
Yan Liu, Chanyue Zhao, Xiaofen Xiong, Ming Yang, Lin Sun
Diabetic Nephropathy.2021; 1(2): 67. CrossRef
Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin
Anwar Ali Jammah
Primary Care Diabetes.2020;[Epub] CrossRef

Author index